Sajjad A. Bhatti

Medical Director of Thoracic Cancers

UAMS

Also affiliated: St. Luke's University Health Network (2025); University of Arkansas Medical Center (2022); Winthrop Rockefeller Foundation (2022)

Faculty Researcher

2 h-index 5 pubs 18 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group

OverviewAI-generated summary

Sajjad A. Bhatti's research focuses on the treatment outcomes and survival of older patients with non-small-cell lung cancer, particularly those with synchronous brain metastases. His work investigates the efficacy and safety of immune checkpoint inhibitors (ICIs) and chemotherapy, both as first-line treatments and subsequent therapies. Bhatti has also explored the role of cranial irradiation in conjunction with ICIs for this patient population. His publications include studies on the real-world survival of patients receiving ICI treatment versus chemotherapy, the efficacy of two-year fixed versus continuous ICI therapy, and the use of ICIs as subsequent treatment in older adults with non-small-cell lung cancer and brain metastases. He also has a publication on sudden vision loss as a presenting symptom of metastatic lung adenocarcinoma. Bhatti's scholarship metrics include an h-index of 2, with 5 total publications and 15 total citations.

Metrics

h-index: 2
Publications: 5
Citations: 18

Selected Publications

Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis (2025)

Current Oncology DOI OpenAlex
An example of long-term remission in oligorecurrent relapsed small-cell lung cancer, following single modality radiation therapy (2025)

BMJ Case Reports DOI OpenAlex
Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation. (2025)

Journal of Clinical Oncology 1 citation DOI OpenAlex
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide. (2025)

Journal of Clinical Oncology DOI OpenAlex
Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review. (2025)

Journal of Clinical Oncology DOI OpenAlex
Association Between Medical Marijuana Cardholder Status and Antiemetic Overuse (2024)

Cannabis and Cannabinoid Research DOI OpenAlex
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases (2024)

Translational Lung Cancer Research 1 citation DOI OpenAlex
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024)

Cancers 2 citations DOI OpenAlex
Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases (2023)

JCO Oncology Practice 13 citations DOI OpenAlex
Participation in a multidisciplinary institutional committee, “RQUEST,” to enhance quality improvement education, project design, and implementation for hematology/oncology fellows. (2023)

Journal of Clinical Oncology DOI OpenAlex
Exploring the association between medical marijuana cardholder status and antiemetic overuse. (2023)

Journal of Clinical Oncology DOI OpenAlex
Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench (2022)

Cancers 6 citations DOI OpenAlex
A RARE CASE OF DESMOPLASTIC SMALL ROUND CELL TUMOR WITH LEPTOMENINGEAL CARCINOMATOSIS (2022)

CHEST Journal 1 citation DOI OpenAlex
Immune Checkpoint Inhibitors—Associated Cardiotoxicity (2022)

Cancers 66 citations DOI OpenAlex